Showing results (671-680 of 2,811) with videos related to
Sort By:
Pageof 282
Expert Opinion on Drug Safety|November 28, 2025
CYP450 activity, drug interactions, and genetic polymorphisms: clinical relevance for the new selective cardiac myosin inhibitorsMilind Y Desai, Veronique Michaud, David Thacker, et al.Expert Opinion on Drug Safety|December 25, 2025
The effectiveness and safety of naldemedine in treating opioid-induced constipation among non-cancer adult patients: updated meta-analysisMohammad M Alnaeem, Khaled H SuleimanExpert Opinion on Drug Safety|November 27, 2025
Comparison of ciprofol and propofol on dreaming and emotional response during painless gastroscopy: a single-center randomized controlled trialLuran Xiong, Kunjie Li, Xinyi Feng, et al.Expert Opinion on Drug Safety|April 27, 2024
A review on side effect management of second-generation antipsychotics to treat schizophrenia: a drug safety perspectiveWolfgang Strube, Elias Wagner, Jurjen J Luykx, et al.Expert Opinion on Drug Safety|April 17, 2024
Immune checkpoint inhibitor related myositis: an observational, retrospective, pharmacovigilance studyHui Yang, Zhexin Ding, Zhuoling An, et al.Expert Opinion on Drug Safety|December 25, 2023
Safety and effectiveness of fifth generation cephalosporins for the treatment of methicillin-resistant staphylococcus aureus bloodstream infections: a narrative review exploring past, present, and futureDavide Fiore Bavaro, Alessandra Belati, Linda Bussini, et al.Expert Opinion on Drug Safety|August 8, 2013
Conjugated estrogens for the treatment of menopausal symptoms: a review of safety dataSebastian Mirkin, Barry S Komm, James H PickarExpert Opinion on Drug Safety|September 13, 2026
A safety review of jak inhibitors for managing alopecia areataKanchalit Thanomkitti, Sofia Spagnolini, Antonella TostiExpert Opinion on Drug Safety|November 21, 2018
Safety of osimertinib in EGFR-mutated non-small cell lung cancerLaura Mezquita, Andreea Varga, David PlanchardExpert Opinion on Drug Safety|April 2, 2019
An update on the safety of SGLT2 inhibitorsAndré J ScheenPageof 282